Page 1 | Search Results | Blood | American Society of Hematology

1-7 of 7

Sort by

Sort Order Select

Journal Articles

KIR Haplotype B Donors but Not KIR-Ligand Mismatch Result in a Reduced Risk of Relapse After Haploidentical Hematopoietic Stem Cell Transplantation Using Reduced Intensity Conditioning and a CD3/CD19 Depleted Graft.

Sebastian Michaelis, cand.med., Markus Mezger, PhD, Martin Bornhauser, MD, Rudolf Trenschel, Gernot Stuhler, MD, Matthias Stelljes, MD, Lutz P Mueller, MD, Herrad Baurmann, MD, Birgit Federmann, MD, Lena Oevermann, MD, Lothar Kanz, MD, Rupert Handgretinger, MD, Wolfgang A. Bethge, MD

Blood (2012) 120 (21): 3101.

https://doi.org/10.1182/blood.V120.21.3101.3101

Published: 2012

Journal Articles

Using Platelet Proteomics as a Marker of Cardiac Failure in a Pacing-Induced Pig Heart Failure Model

Stephen W. Rothwell, PhD, Mark C. Haigney, Shao-kui Wi, Madelaine Clark, Ofer Eidelman, Catherine Jozwik, Meera Srivastava, Gregory P. Mueller, Matie Shou, Harvey B. Pollard

Blood (2008) 112 (11): 4535.

https://doi.org/10.1182/blood.V112.11.4535.4535

Published: 2008

Journal Articles

Prognostic Factors and Treatment Outcome in Lymphocyte Predominant and Classical Hodgkin’s Lymphoma: A Comprehensive Analysis of the German Hodgkin Study Group.

Lucia Nogova, MD, Thorsten Reineke, Corinne Brillant, Thomas Ruediger, Prof, Hans K. Mueller-Hermelink, Prof., Henning Bredenfeld, MD, Andreas Josting, MD, Rolf P. Mueller, Prof., Volker Diehl, Prof., Andreas Engert, Prof.

Blood (2006) 108 (11): 97.

https://doi.org/10.1182/blood.V108.11.97.97

Published: 2006

Journal Articles

Combined Modality Treatment of Two or Four Cycles of ABVD Followed by Involved Field Radiotherapy in the Treatment of Patients with Early Stage Hodgkin’s Lymphoma: Update Interim Analysis of the Randomised HD10 Study of the German Hodgkin Study Group (GHSG).

Andreas Engert, Annette Pluetschow, Hans T. Eich, Richard Herrmann, Bernd Doerken, Lothar Kanz, Richard Greil, Jana Markova, Beate Pfistner, Andreas Josting, Konrad Mueller-Hermelink, Ralf P. Mueller, Volker Diehl

Blood (2005) 106 (11): 2673.

https://doi.org/10.1182/blood.V106.11.2673.2673

Published: 2005

Journal Articles

Reduction of Combined Modality Treatment Intensity in Early Stage Hodgkin’s Lymphoma: Interim Analysis of the HD 10 Trial of the GHSG.

Volker Diehl, C. Brillant, A. Engert, J. Wolf, L. Nogova, R.-P. Mueller, H. Eich, H.K. Mueller-Hermelink, R. Herrmann, B. Doerken, L. Kanz, R. Greil, B. Pfistner, for the German Hodgkin′s lymphoma study group (GHSG), the Competence Network Malignant Lymphoma.

Blood (2004) 104 (11): 1307.

https://doi.org/10.1182/blood.V104.11.1307.1307

Published: 2004

Journal Articles

Intensification of Chemotherapy and Concomitant Reduction of Radiotherapy Dose in Intermediate Stage Hodgkin′s Lymphoma: Results of the Fourth Interim Analysis of the HD 11 Trial of the GHSG.

Volker Diehl, C. Brillant, A. Engert, J. Wolf, L. Nogova, R.-P. Mueller, H. Eich, H.K. Mueller Hermelink, R. Herrman, J. Markova, A. Ho, W. Hiddemann, B. Doerken, R. Greil, B. Pfistner, for the German Hodgkin′s Lymphoma Study Group (GHSG), the Competence Network Malignant Lymphoma.

Blood (2004) 104 (11): 1308.

https://doi.org/10.1182/blood.V104.11.1308.1308

Published: 2004

Journal Articles

Randomized, double-blind, placebo-controlled, phase III study of recombinant human granulocyte-macrophage colony-stimulating factor as adjunct to induction treatment of high-grade malignant non-Hodgkin's lymphomas [see comments]

HH Gerhartz, M Engelhard, P Meusers, G Brittinger, W Wilmanns, G Schlimok, P Mueller, D Huhn, R Musch, W Siegert

Blood (1993) 82 (8): 2329–2339.

https://doi.org/10.1182/blood.V82.8.2329.2329

Published: 1993

NARROW

KIR Haplotype B Donors but Not KIR-Ligand Mismatch Result in a Reduced Risk of Relapse After Haploidentical Hematopoietic Stem Cell Transplantation Using Reduced Intensity Conditioning and a CD3/CD19 Depleted Graft.

Using Platelet Proteomics as a Marker of Cardiac Failure in a Pacing-Induced Pig Heart Failure Model

Prognostic Factors and Treatment Outcome in Lymphocyte Predominant and Classical Hodgkin’s Lymphoma: A Comprehensive Analysis of the German Hodgkin Study Group.

Combined Modality Treatment of Two or Four Cycles of ABVD Followed by Involved Field Radiotherapy in the Treatment of Patients with Early Stage Hodgkin’s Lymphoma: Update Interim Analysis of the Randomised HD10 Study of the German Hodgkin Study Group (GHSG).

Reduction of Combined Modality Treatment Intensity in Early Stage Hodgkin’s Lymphoma: Interim Analysis of the HD 10 Trial of the GHSG.

Intensification of Chemotherapy and Concomitant Reduction of Radiotherapy Dose in Intermediate Stage Hodgkin′s Lymphoma: Results of the Fourth Interim Analysis of the HD 11 Trial of the GHSG.

Randomized, double-blind, placebo-controlled, phase III study of recombinant human granulocyte-macrophage colony-stimulating factor as adjunct to induction treatment of high-grade malignant non-Hodgkin's lymphomas [see comments]

Email alerts

ASH Publications

American Society of Hematology

KIR Haplotype B Donors but Not KIR-Ligand Mismatch Result in a Reduced Risk of Relapse After Haploidentical Hematopoietic Stem Cell Transplantation Using Reduced Intensity Conditioning and a CD3/CD19 Depleted Graft.

Using Platelet Proteomics as a Marker of Cardiac Failure in a Pacing-Induced Pig Heart Failure Model

Prognostic Factors and Treatment Outcome in Lymphocyte Predominant and Classical Hodgkin’s Lymphoma: A Comprehensive Analysis of the German Hodgkin Study Group.

Combined Modality Treatment of Two or Four Cycles of ABVD Followed by Involved Field Radiotherapy in the Treatment of Patients with Early Stage Hodgkin’s Lymphoma: Update Interim Analysis of the Randomised HD10 Study of the German Hodgkin Study Group (GHSG).

Reduction of Combined Modality Treatment Intensity in Early Stage Hodgkin’s Lymphoma: Interim Analysis of the HD 10 Trial of the GHSG.

Intensification of Chemotherapy and Concomitant Reduction of Radiotherapy Dose in Intermediate Stage Hodgkin′s Lymphoma: Results of the Fourth Interim Analysis of the HD 11 Trial of the GHSG.

Randomized, double-blind, placebo-controlled, phase III study of recombinant human granulocyte-macrophage colony-stimulating factor as adjunct to induction treatment of high-grade malignant non-Hodgkin's lymphomas [see comments]

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only